PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Unlocking new talents in nature

Caltech protein engineers create new biocatalysts

2012-12-21
(Press-News.org) PASADENA, Calif.—Protein engineers at the California Institute of Technology (Caltech) have tapped into a hidden talent of one of nature's most versatile catalysts. The enzyme cytochrome P450 is nature's premier oxidation catalyst—a protein that typically promotes reactions that add oxygen atoms to other chemicals. Now the Caltech researchers have engineered new versions of the enzyme, unlocking its ability to drive a completely different and synthetically useful reaction that does not take place in nature.

The new biocatalysts can be used to make natural products—such as hormones, pheromones, and insecticides—as well as pharmaceutical drugs, like antibiotics, in a "greener" way.

"Using the power of protein engineering and evolution, we can convince enzymes to take what they do poorly and do it really well," says Frances Arnold, the Dick and Barbara Dickinson Professor of Chemical Engineering, Bioengineering and Biochemistry at Caltech and principal investigator on a paper about the enzymes that appears online in Science. "Here, we've asked a natural enzyme to catalyze a reaction that had been devised by chemists but that nature could never do."

Arnold's lab has been working for years with a bacterial cytochrome P450. In nature, enzymes in this family insert oxygen into a variety of molecules that contain either a carbon-carbon double bond or a carbon-hydrogen single bond. Most of these insertions require the formation of a highly reactive intermediate called an oxene.

Arnold and her colleagues Pedro Coelho and Eric Brustad noted that this reaction has a lot in common with another reaction that synthetic chemists came up with to create products that incorporate a cyclopropane—a chemical group containing three carbon atoms arranged in a triangle. Cyclopropanes are a necessary part of many natural-product intermediates and pharmaceuticals, but nature forms them through a complicated series of steps that no chemist would want to replicate.

"Nature has a limited chemical repertoire," Brustad says. "But as chemists, we can create conditions and use reagents and substrates that are not available to the biological world."

The cyclopropanation reaction that the synthetic chemists came up with inserts carbon using intermediates called carbenes, which have an electronic structure similar to oxenes. This reaction provides a direct route to the formation of diverse cyclopropane-containing products that would not be accessible by natural pathways. However, even this reaction is not a perfect solution because some of the solvents needed to run the reaction are toxic, and it is typically driven by catalysts based on expensive transition metals, such as copper and rhodium. Furthermore, tweaking these catalysts to predictably make specific products remains a significant challenge—one the researchers hoped nature could overcome with evolution's help.

Given the similarities between the two reaction systems—cytochrome P450's natural oxidation reactions and the synthetic chemists' cyclopropanation reaction— Arnold and her colleagues argued that it might be possible to convince the bacterial cytochrome P450 to create cyclopropane-bearing compounds through this more direct route. Their experiments showed that the natural enzyme (cytochrome P450) could in fact catalyze the reaction, but only very poorly; it generated a low yield of products, didn't make the specific mix of products desired, and catalyzed the reaction only a few times. In comparison, transition-metal catalysts can be used hundreds of times.

That's where protein engineering came in. Over the years, Arnold's lab has created thousands of cytochrome P450 variants by mutating the enzyme's natural sequence of amino acids, using a process called directed evolution. The researchers tested variants from their collections to see how well they catalyzed the cyclopropane-forming reaction. A handful ended up being hits, driving the reaction hundreds of times.

Being able to catalyze a reaction is a crucial first step, but for a chemical process to be truly useful it has to generate high yields of specific products. Many chemical compounds exist in more than one form, so although the chemical formulas of various products may be identical, they might, for example, be mirror images of each other or have slightly different bonding structures, leading to dissimilar behavior. Therefore, being able to control what forms are produced and in what ratio—a quality called selectivity—is especially important.

Controlling selectivity is difficult. It is something that chemists struggle to do, while nature excels at it. That was another reason Arnold and her team wanted to investigate cytochrome P450's ability to catalyze the reaction.

"We should be able to marry the impressive repertoire of catalysts that chemists have invented with the power of nature to do highly selective chemistry under green conditions," Arnold says.

So the researchers further "evolved" enzyme variants that had worked well in the cyclopropanation reaction, to come up with a spectrum of new enzymes. And those enzymes worked—they were able to drive the reaction many times and produced many of the selectivities a chemist could desire for various substrates.

Coelho says this work highlights the utility of synthetic chemistry in expanding nature's catalytic potential. "This field is still in its infancy," he says. "There are many more reactions out there waiting to be installed in the biological world."

### The paper, "Olefin cyclopropanation via carbene insertion catalyzed by engineered cytochrome P450 enzymes," was also coauthored by Arvind Kannan, now a Churchill Scholar at Cambridge University; Brustad is now an assistant professor at the University of North Carolina at Chapel Hill. The work was supported by a grant from the U.S. Department of Energy and startup funds from UNC Chapel Hill.


ELSE PRESS RELEASES FROM THIS DATE:

To outsmart malarial drug resistance, research team develops new whole-plant strategy

To outsmart malarial drug resistance, research  team develops new whole-plant strategy
2012-12-21
AMHERST, Mass. – Malaria brings misery and death to millions in the developing world each year, and fighting it keeps medical researchers up at night because the mosquito-borne parasite Plasmodium falciparum, which causes the deadliest form of the disease, has developed resistance to every drug thrown at it. Resistance has cut short the useful life of nearly every therapy tried so far, experts say. But now molecular parasitologist Stephen Rich at the University of Massachusetts Amherst has led a research team who report a promising new low-cost combined therapy with a ...

New MRI analysis useful in predicting stroke complications caused by clot-busters

2012-12-21
Johns Hopkins researchers have developed a new way of looking at standard MRI scans that more accurately measures damage to the blood-brain barrier in stroke victims, a process they hope will lead to safer, more individualized treatment of blood clots in the brain and better outcomes. The blood-brain barrier is a unique shielding of blood vessels that limits the passage of molecules from the blood stream into the brain. Without it, the brain is open to infection, inflammation and hemorrhage. Ischemic stroke patients are at risk of bleeding into the brain when there is ...

Research reveals new drug target urgently needed for tuberculosis therapy

2012-12-21
One third of the world is infected with the bacterium that causes tuberculosis (TB), a disease that is increasingly difficult to treat because of wide spread resistance to available drugs. Researchers from the Institute of Pharmacology and Structural Biology (CNRS, Université de Toulouse) in Toulouse (France) have identified a fresh target to develop new drugs for TB. The study, published in the Open Access journal PLOS Pathogens, shows why the target will be important in developing new TB treatments. The deadliest form of human tuberculosis is caused by Mycobacterium ...

Brain imaging insight into cannabis as a pain killer

2012-12-21
The pain relief offered by cannabis varies greatly between individuals, a brain imaging study carried out at the University of Oxford suggests. The researchers found that an oral tablet of THC, the psychoactive ingredient in cannabis, tended to make the experience of pain more bearable, rather than actually reduce the intensity of the pain. MRI brain imaging showed reduced activity in key areas of the brain that substantiated the pain relief the study participants experienced. 'We have revealed new information about the neural basis of cannabis-induced pain relief,' ...

Microevolutionary analysis of Clostridium difficile genomes to investigate transmission

2012-12-21
Over recent years, hospital-acquired Clostridium difficile infections have been a significant problem in UK hospitals and globally. There have been concerns that infections may be due to transmission between symptomatic patients, either directly, or indirectly via hospital staff; these concerns were strengthened when enhanced infection control was introduced in England in 2007, and the incidence of C. difficile infection declined. A recent study published in the open access journal Genome Biology, published by BioMed Central, took a genomics approach to assess the incidence ...

Newborn baby screening for fragile X syndrome

2012-12-21
A study into newborn screening for fragile X syndrome (FXS) demonstrates that testing for mutations in the gene FMR1 can be done on a large scale. The research, published in BioMed Central's open access journal Genome Medicine, shows that the number of carrier babies who carry the form of the gene known as the "premutation" is higher than previously estimated. Three large hospitals in the USA participated in this study, testing more than 14,000 newborns, including children of different ethnic backgrounds. While only one child was identified with the full mutation, the ...

Cancer diagnosis later in life poses significant risk to offspring

2012-12-21
Relatives of family members diagnosed with cancer are still at risk of the disease even if the diagnosis came at an older age, suggests a paper published on bmj.com today. It is known that early onset cancer cases carry more hereditary risk than late onset cases, but little is known about whether any familial component exists in cancer at a very old age. Researchers from the German Cancer Research Centre and Lund University in Sweden therefore took data from the Swedish Family-Cancer Database (the largest one of its kind) on just under eight million offspring and their ...

Genetic differences may influence sensitivity to pain, according to new study

2012-12-21
The study, published in PLOS Genetics on 20 December, adds to growing evidence that particular genes are involved in chronic pain and highlights this pathway as a potential target for more effective pain relief treatments for patients. The collaborative study between King's, Pfizer Ltd and the Beijing Genomics Institute (BGI), used a new method to study and compare DNA, called 'exome sequencing', to identify genetic variations relating to pain sensitivity. Lead author Dr Frances Williams, from the Department of Twin Research and Genetic Epidemiology at King's College ...

New whole plant therapy shows promise as an effective and economical treatment for malaria

New whole plant therapy shows promise as an effective and economical treatment for malaria
2012-12-21
Worcester, Mass. – In the worldwide battle to curtail malaria, one of the most prevalent and deadly infectious diseases of the developing world, drug after drug has fallen by the wayside as the malaria parasite has become resistant to it. Only artemisinin, derived from the sweet wormwood plant, Artemisia annua, remains as an effective treatment, but it is expensive to produce (particularly when combined with other antimalarial medications to make it less prone to resistance) and is frequently in short supply. A new study by scientists at Worcester Polytechnic Institute ...

Genetic defect causing fragile X-related disorders more common than thought

2012-12-21
A single genetic defect on the X chromosome that can result in a wide array of conditions — from learning and emotional difficulties to primary ovarian insufficiency in women and tremors in middle-aged men — occurs at a much greater frequency than previously thought, research led by the UC Davis MIND Institute has found. The research is based on the first large-scale, multi-center newborn screening effort for the defect in the United States, conducted in a group of more than 14,200 male and female infants at three research university medical centers piloting a new infant ...

LAST 30 PRESS RELEASES:

New superconductor with hallmark of unconventional superconductivity discovered

Global HIV study finds that cardiovascular risk models underestimate for key populations

New study offers insights into how populations conform or go against the crowd

Development of a high-performance AI device utilizing ion-controlled spin wave interference in magnetic materials

WashU researchers map individual brain dynamics

Technology for oxidizing atmospheric methane won’t help the climate

US Department of Energy announces Early Career Research Program for FY 2025

PECASE winners: 3 UVA engineering professors receive presidential early career awards

‘Turn on the lights’: DAVD display helps navy divers navigate undersea conditions

MSU researcher’s breakthrough model sheds light on solar storms and space weather

Nebraska psychology professor recognized with Presidential Early Career Award

New data shows how ‘rage giving’ boosted immigrant-serving nonprofits during the first Trump Administration

Unique characteristics of a rare liver cancer identified as clinical trial of new treatment begins

From lab to field: CABBI pipeline delivers oil-rich sorghum

Stem cell therapy jumpstarts brain recovery after stroke

Polymer editing can upcycle waste into higher-performance plastics

Research on past hurricanes aims to reduce future risk

UT Health San Antonio, UTSA researchers receive prestigious 2025 Hill Prizes for medicine and technology

Panorama of our nearest galactic neighbor unveils hundreds of millions of stars

A chain reaction: HIV vaccines can lead to antibodies against antibodies

Bacteria in polymers form cables that grow into living gels

Rotavirus protein NSP4 manipulates gastrointestinal disease severity

‘Ding-dong:’ A study finds specific neurons with an immune doorbell

A major advance in biology combines DNA and RNA and could revolutionize cancer treatments

Neutrophil elastase as a predictor of delivery in pregnant women with preterm labor

NIH to lead implementation of National Plan to End Parkinson’s Act

Growth of private equity and hospital consolidation in primary care and price implications

Online advertising of compounded glucagon-like peptide-1 receptor agonists

Health care utilization and costs for older adults aging into Medicare after the affordable care act

Reading the genome and understanding evolution: Symbioses and gene transfer in leaf beetles

[Press-News.org] Unlocking new talents in nature
Caltech protein engineers create new biocatalysts